BARD1 Life Sciences Ltd
ASX:BD1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BARD1 Life Sciences Ltd
Gross Profit
BARD1 Life Sciences Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BARD1 Life Sciences Ltd
ASX:BD1
|
Gross Profit
AU$446.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Gross Profit
AU$8.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Gross Profit
AU$734.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Gross Profit
AU$613m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Apiam Animal Health Ltd
ASX:AHX
|
Gross Profit
AU$137m
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Gross Profit
AU$1.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-2%
|
|
BARD1 Life Sciences Ltd
Glance View
BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.
See Also
What is BARD1 Life Sciences Ltd's Gross Profit?
Gross Profit
446.9k
AUD
Based on the financial report for Jun 30, 2021, BARD1 Life Sciences Ltd's Gross Profit amounts to 446.9k AUD.
